Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Jan 12, 2021 5:13pm
180 Views
Post# 32278854

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:No follow through

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:No follow throughBio have you heard of the HemAcure Project?   Just happens that they are using the cell pouch for hemophilia.  Take a look at the NR last May had some great preclinical results and it will likely be progressing to the clinic in the near future and when you speak of being short on cash this is grant money. Would definitely be nice to see us entering the clinic for Hemophilia Q1 2021 would make SGTX valuation gap even more obviouse/ridiculous..

"These promising results of the HemAcure consortium are paving the way for future human clinical testing in hemophilia A patients using Sernova's technologies transplanted with corrected FVIII cells developed by this prestigious international team. This initiative continues to support the value of collaborative efforts involving Sernova's regenerative medicine technologies in both diabetes and now rare diseases such as hemophilia A," said Dr. Philip Toleikis, President and CEO of Sernova Corp.

https://stockhouse.com/news/press-releases/2020/05/19/sernova-highlights-achievements-of-the-hemacure-hemophilia-cell-therapy-program
<< Previous
Bullboard Posts
Next >>